Search results: Found 2

Listing 1 - 2 of 2
Sort by
Good News - Bad News: The Two Faces of Immune Privilege

Authors: ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889193318 Year: Pages: 109 DOI: 10.3389/978-2-88919-331-8 Language: English
Publisher: Frontiers Media SA
Subject: Allergy and Immunology --- Medicine (General)
Added to DOAB on : 2016-03-10 08:14:32
License:

Loading...
Export citation

Choose an application

Abstract

Immune privilege was once thought to be the property of a few select sites that include the eye, brain, testis, pregnant uterus and (of all things) the hamster cheek pouch, and was believed to be mainly based on sequestration behind blood-tissue barriers. This view has changed. Immune privilege is now considered to constitute a more general phenomenon through which tissues are able to actively direct and control immune responses taking place in their “territory” to preserve their structural and functional integrity in the face of inflammatory processes. These positive aspects of immune privilege can be hijacked by tumors to their survival advantage and to the detriment of the host. This Research Topic dissects the beneficial and deleterious consequences of immune privilege in terms of the cellular and molecular mechanisms that various tissues and tumors use, each in its own fashion, to regulate immune processes that affect them, at the local and the systemic level.

Cancer Immunotherapy & Immuno-monitoring: Mechanism, Treatment, Diagnosis, and Emerging Tools

Authors: --- ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889193806 Year: Pages: 97 DOI: 10.3389/978-2-88919-380-6 Language: English
Publisher: Frontiers Media SA
Subject: Oncology --- Medicine (General)
Added to DOAB on : 2015-12-03 13:02:24
License:

Loading...
Export citation

Choose an application

Abstract

In the past decade, significant progresses have taken place in the field of cancer immunotherapy. Tumor-targeting immunotherapies are being developed for most human cancers, including melanoma, prostate cancer, glioblastoma, sarcoma, lung carcinoma and hepatocellular carcinoma. The FDA has approved multiple molecular immunotherapeutics, such as Ipilimumab; cellular immunotherapies (e.g. adoptive cell transfer) are being tested in phase II/III clinical trials. Immunotherapetics has evolved into a sophisticated field: Multimodal therapeutic regimens are administrated to induce focused responses, curtail side- effects and improve therapeutic efficacy. The lack of effective clinical assessment tools remains a major challenge. Because of the intricacy of antitumor response, it is essential to scrutinize individual tumor-targeting immune cells and their functions at the finest details - molecules. In this regard, flow cytometry analysis modernized hematology and allows characterization of surface molecular signature on individual cells. More recently, microchip technologies and new variations of cytometry have enormously expanded the spectrum, throughout and multiplexity of single cell analysis. Nowadays, tens of millions of readouts can be generated through the course of a cancer immunotherapy to monitor the abundance, phenotype and a myriad of effector functions of single immune cells. At the same time, big data analytics and data mining methodologies have been adapted to achieve sensible diagnostic interpretations. Such a marriage of technology and analytics opens the door for informative point-of-care assessment of therapeutic efficacy and ensures timely therapeutic decisions. The new generation of personalized clinical diagnostics will revolutionize healthcare in the years to come.

Listing 1 - 2 of 2
Sort by
Narrow your search

Publisher

Frontiers Media SA (2)


License

CC by (2)


Language

english (2)


Year
From To Submit

2014 (2)